natgillin/translations-raw huggingface dataset:
Treatment should be discontinued in case of life-threatening reactions (e.g., Grade 4) with the exception of laboratory abnormality judged to be non-life-threatening, in which case they should be managed as severe reaction (e.g., Grade 3).
Zdravljenje je treba prekiniti v primeru smrtno nevarnih neželenih učinkov (npr. stopnje 4), z izjemo laboratorijskih nenormalnosti, za katere sodimo, da niso smrtno nevarne; v tem primeru jih obravnavajte kot hude neželene učinke (npr.stopnje 3).
Treatment should be discontinued in case of:
Z zdravljenjem je treba prenehati v primeru:
Treatment should be discontinued in patients who show no response after 12 weeks.
Če pri bolniku po 12 tednih ni odziva, je treba zdravljenje prekiniti.
Treatment should be discontinued in patients with platelet count less than 50,000/mm3 or absoute neutrophil count less than 500/mm3 (see section 4.2).
Pri številu trombocitov pod 50.000/mm3 oziroma absolutnem številu nevtrofilcev pod 500/mm3 je treba zdravljenje prekiniti (glejte poglavje 4.2).
treatment should be discontinued until the event has returned to grade 1 the time of injection of the dose of Ceplene should be extended to a maximum of 15 minutes. for cardiac, hepatic or renal toxicities the dose should be reduced by 20% for both Ceplene and IL-2.
zdravljenje je treba prekiniti, dokler se dogodki ne povrnejo na 1. stopnjo, čas injiciranja odmerka zdravila Ceplene podaljšajte na največ 15 minut, pri srčni, jetrni ali ledvični toksičnosti odmerka tako zdravila Ceplene kot IL-2 zmanjšajte za 20 %.
Treatment should be discontinued upon progression of disease.
Zdravljenje je treba ob napredovanju bolezni ukiniti.
Treatment should be discontinued, delayed, or the dose may have to be adjusted, in patients who develop certain side effects.
Pri bolnikih, pri katerih se pojavijo nekateri neželeni učinki, je treba zdravljenje prekiniti ali odložiti ali pa odmerek prilagoditi.
Treatment should be discontinued, if severe adverse reactions are still encountered at the 6 mg/kg/day dose.
Če se neželene reakcije pojavljajo tudi pri odmerku 6 mg/kg/dan, je treba z zdravljenjem prenehati.
Treatment should be discontinued, if severe adverse reactions are still encountered at the 6 mg/kg/day dose.
Če se neželeni učinki pojavljajo tudi pri odmerku 6 mg/kg/dan, je treba z zdravljenjem prenehati.
Treatment should be given once daily for 3 consecutive days.
Zdravljenje traja 3 zaporedne dni, enkrat dnevno.
Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia or dementia associated with Parkinson’s disease.
Zdravljenje mora uvesti in nadzorovati zdravnik, ki je izkušen v diagnostiki in zdravljenju Alzheimerjeve demence ali demence, povezane s Parkinsonovo boleznijo.
Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia or dementia associated with Parkinson’s disease.
Zdravljenje mora začeti in nadzirati zdravnik z izkušnjami v diagnosticiranju in zdravljenju Alzheimerjeve demence ali demence, povezane s Parkinsonovo boleznijo.
Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia.
Zdravljenje mora uvesti in nadzorovati zdravnik, ki je izkušen v diagnostiki in zdravljenju Alzheimerjeve demence.
Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia.
Zdravljenje naj prične in nadzoruje zdravnik, ki ima izkušnje z diagnozo in zdravljenjem Alzheimerjeve demence.
Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia.
Zdravljenje naj začne in nadzoruje zdravnik, ki ima izkušnje z diagnozo in zdravljenjem Alzheimerjeve demence.
Treatment should be initiated and supervised by a physician with experience in LHON.
Zdravljenje mora začeti in nadzorovati zdravnik z izkušnjami z LHON.
Treatment should be initiated and supervised by physicians experienced in endocrinology or internal medicine and having the appropriate facilities for monitoring of biochemical responses since the dose must be adjusted to meet the patient’s therapeutic need, based on the normalisation of cortisol levels.
Zdravljenje morajo uvesti in nadzorovati zdravniki z izkušnjami z endokrinologijo ali interno medicino, ki imajo na voljo ustrezno opremo za spremljanje biokemičnih odzivov, saj je treba odmerek prilagoditi glede na bolnikovo terapevtsko potrebo, ki temelji na normalizaciji ravni kortizola.
Treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of rheumatoid arthritis or JIA.
Zdravljenje mora uvesti in nadzirati zdravnik specialist, ki ima izkušnje z diagnosticiranjem in zdravljenjem revmatoidnega artritisa ali JIA.
Treatment should be initiated as soon as possible within the first two days of onset of symptoms of influenza.
Zdravljenje je treba začeti čim prej v prvih dveh dneh po nastopu simptomov gripe.
Treatment should be initiated at 300 mg (3.75 ml) twice daily for a period of three days and increased by 100 mg (1.25 ml) twice daily increments up to 600 mg twice daily over a period of no longer than 14 days.
Zdravljenje je treba začeti s 300 mg (3,75 ml) dvakrat na dan v obdobju 3 dni in odmerek zvečevati po 100 mg (1,25 ml) dvakrat na dan do 600 mg dvakrat na dan v obdobju, ki ne presega 14 dni.
Treatment should be initiated at a daily dose of 200 mg.
Zdravljenje je treba začeti z dnevnim odmerkom 200 mg.
Treatment should be initiated by and remain under the supervision of a physician experienced in the management of opioid therapy in cancer patients.
Zdravljenje mora uvesti in ves čas nadzirati zdravnik, ki ima izkušnje z opioidnim zdravljenjem pri bolnikih z rakom.
Treatment should be initiated by healthcare professionals experienced in the diagnosis and treatment of RA, sJIA or pJIA.
Zdravljenje mora vpeljati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem revmatoidnega artritisa, sJIA ali poliartikularnega juvenilnega idiopatskega poliartritisa (pJIA).
Treatment should be initiated by healthcare professionals experienced in the diagnosis and treatment of RA.
Zdravljenje mora vpeljati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem revmatoidnega artritisa.
Treatment should be initiated by healthcare professionals experienced in the diagnosis and treatment of RA.
Zdravljenje s tem zdravilom mora vpeljati zdravstveni delavec z izkušnjami pri diagnosticiranju in zdravljenju revmatoidnega artritisa.
Treatment should be initiated only by a physician experienced in the treatment of patients with hepatitis B or C.
Zdravljenje lahko začne le zdravnik, ki ima izkušnje z zdravljenjem bolnikov s hepatitisom B ali C.
Treatment should be initiated orally within 1-4 hours of completed surgery with a single capsule of 110 mg and continuing with 2 capsules once daily thereafter for a total of 10 days.
Zdravljenje z zdravilom Pradaxa moramo začeti peroralno, 1 do 4 ure po končani operaciji, z eno kapsulo po 110 mg in ga nadaljevati z 2 kapsulama, enkrat na dan, skupno 10 dni.
Treatment should be initiated orally within 1-4 hours of completed surgery with a single capsule of 110 mg and continuing with 2 capsules once daily thereafter for a total of 28-35 days.
Zdravljenje z zdravilom Pradaxa moramo začeti peroralno, 1 do 4 ure po končani operaciji, z eno kapsulo po 110 mg in ga nadaljevati z 2 kapsulama, 1-krat na dan, skupno 28 do 35 dni.
Treatment should be initiated orally within 1-4 hours of completed surgery with a single capsule of 75 mg and continuing with 2 capsules once daily thereafter for a total of 10 days (knee replacement surgery) or 28-35 days (hip replacement surgery):
Zdravljenje je treba začeti peroralno 1 do 4 ure po končani operaciji z eno kapsulo po 75 mg, nato pa nadaljevati z 2 kapsulama enkrat na dan, toliko časa, da bo skupno trajalo 10 dni (pri vstavitvi umetnega kolena) oziroma 28 do 35 dni (pri vstavitvi umetnega kolka):
Treatment should be initiated orally within 1-4 hours of completed surgery with a single of 110 mg capsule and continuing with 2 capsules once daily thereafter for a total of 10 days.
Zdravljenje z zdravilom Pradaxa moramo začeti peroralno, 1 do 4 ure po končani operaciji, z eno kapsulo po 110 mg in ga nadaljevati z 2 kapsulama, enkrat na dan, skupno 10 dni.
Treatment should be initiated under supervision of a physician experienced in the treatment of multiple sclerosis.
Zdravljenje naj se začne pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem multiple skleroze.
Treatment should be initiated under supervision of a physician experienced in the treatment of the disease.
Zdravljenje naj se začne pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem te bolezni.
Treatment should be initiated under supervision of a physician experienced in the treatment of the disease.
Zdravljenje se mora pričeti pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem te bolezni.
Treatment should be initiated under the supervision of a doctor experienced in the treatment of haemophilia.
Zdravljenje se mora začeti pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem hemofilije.
Treatment should be initiated under the supervision of a medical professional with experience in the treatment of paediatric SBS.
Zdravljenje se mora začeti pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem SKČ pri otrocih.
Treatment should be initiated under the supervision of a medical professional with experience in the treatment of Short Bowel Syndrome (SBS).
Zdravljenje se mora začeti pod nadzorom zdravstvenega delavca, ki ima izkušnje z zdravljenjem sindroma kratkega črevesa (SKČ).
Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia.
Zdravljenje je treba začeti pod nadzorom zdravnika, izkušenega v zdravljenju hemofilije.
Treatment should be initiated with a loading dose of 4.4 mg/kg, up to a maximum of 320 mg.
Zdravljenje naj se uvede s polnitvenim odmerkom 4,4 mg/kg do največ 320 mg.
Treatment should be initiated with a loading dose of 4.4 mg/kg, up to a maximum of 320 mg.
Zdravljenje naj se uvede s polnitvenim odmerkom 4,4 mg/kg, do največ 320 mg.
Treatment should be interrupted in patients who report symptoms that may indicate acute uric acid nephropathy including flank pain, nausea or vomiting, and measure serum creatinine promptly.
Zdravljenje je treba prekiniti pri bolnikih s simptomi, ki lahko kažejo na akutno urično nefropatijo: npr. z bolečinami v ledvenem predelu, navzeo ali bruhanjem; v tem primeru takoj izmerite kreatinin v serumu.
Treatment should be regularly evaluated in the individual patient weighing the risk for ischaemic events against the bleeding risks.
Pri posameznem bolniku je treba realno oceniti zdravljenje in pretehtati tveganje za ishemični dogodek glede na tveganje za krvavitev.
Treatment should be reinitiated using the next lowest dose of cinacalcet.
Ob ponovnem začetku zdravljenja je treba uporabiti naslednji najnižji odmerek cinakalceta.
Treatment should be reinitiated using the next lowest dose of Mimpara.
Ob ponovnem začetku zdravljenja je treba uporabiti naslednji najnižji odmerek zdravila Mimpara.
Treatment should be repeated at monthly intervals during the flea or tick seasons.
Zdravljenje je med sezono bolh in klopov treba ponavljati vsak mesec.
Treatment should be repeated at monthly intervals during the flea or tick seasons.
Zdravljenje je treba med sezono bolh ali klopov ponavljati vsak mesec.
Treatment should be repeated every twelve weeks for optimal flea and tick control.
Za optimalen nadzor nad bolhami in klopi je treba zdravljenje ponoviti vsakih 12 tednov.
Treatment should be repeated every twelve weeks for optimal flea control.
Za optimalen nadzor nad bolhami je treba zdravljenje ponoviti vsakih dvanajst tednov.
Treatment should be reviewed weekly for the first six weeks and every six weeks thereafter or at intervals deemed appropriate by the veterinarian.
Zdravljenje je potrebno preverjati prvih šest tednov tedensko, nato vsakih šest tednov ali v intervalih po presoji veterinarja.
Treatment should be started and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer’s disease.
Zdravljenje mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem Alzheimerjeve bolezni.
Treatment should be started and supervised by a doctor who has experience in treating medullary thyroid cancer, using anticancer medicines and assessing electrocardiograms (ECG, a test that measures the electrical activity of the heart).
Zdravljenje mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem medularnega raka ščitnice, z uporabo zdravil proti raku in ocenitvami s pomočjo elektrokardiograma (EKG, testa, ki meri električno aktivnost srca).
Treatment should be started as early as possible and the dose of Orfadin adjusted according to the patient’s response and body weight.
Zdravljenje je treba začeti čim prej, odmerek zdravila pa je treba prilagoditi bolnikovemu odzivu in telesni masi.
Treatment should be started as soon as possible after diagnosis and continued for up to eight days or until the patient is discharged from hospital.
Zdravljenje se mora pričeti takoj po diagnozi in mora trajati do osem dni ali do odpusta bolnika iz bolnišnice.
Treatment should be started at a dose of 50 mg a day and the doctor may increase the dose up to 100 mg a day based on patient’s need.
Zdravljenje je treba začeti z odmerkom 50 mg na dan, zdravnik pa lahko odmerek glede na bolnikove potrebe poveča na največ 100 mg.
Treatment should be started at a single dose of 0.2 mg/kg body weight on the first day, and then continued at a maintenance dose of 0.1 mg/kg body weight once a day.
Zdravljenje se začne z enim odmerkom 0,2 mg/kg telesne mase prvi dan in nato nadaljuje z vzdrževalnim odmerkom 0,1 mg/kg telesne mase enkrat na dan.
Treatment should be started under the supervision of a doctor with experience in treating short bowel syndrome.
Zdravljenje je treba začeti pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem sindroma kratkega črevesa.
Treatment should be started with Protopic 0.1% twice a day and treatment should be continued until clearance of the lesion.
Zdravljenje je treba začeti z zdravilom Protopic 0,1% dvakrat na dan in ga nadaljevati, dokler spremembe ne izginejo.
Treatment should be stopped if seizures occur.
Če pride do napadov krčev, je treba zdravljenje prekiniti.
Treatment should be stopped if the patient develops any of the contraindicated conditions (see section 4.3 of the SmPC).
Zdravljenje je treba ukiniti, če se bolniku pojavi katero od kontraindiciranih stanj (glejte poglavje 4.3 v povzetku glavnih značilnosti zdravila).
Treatment should be stopped if the patient’s blood levels of platelets or neutrophils (a type of white blood cell) fall below certain thresholds, or if no improvement in spleen size or symptoms is seen after six months.
Zdravljenje je treba prekiniti, če se vrednosti krvnih ploščic ali nevtrofilcev (vrste belih krvnih celic) v bolnikovi krvi znižajo pod določeno vrednost ali če se velikost vranice ali simptomi po šestih mesecih zdravljenja ne izboljšajo.
Treatment should be stopped immediately in this case.
V tem primeru je treba takoj prekiniti zdravljenje.
Treatment should be symptomatic and general supportive measures should be utilised.
Zdravljenje mora biti simptomatsko in uporabiti je treba splošne podporne ukrepe.
Treatment should be tailored to the individual patient’s response as assessed by measuring follicle size by ultrasound and oestrogen response.
Zdravljenje mora biti prilagojeno individualnemu odzivu bolnice, katerega ovrednotimo z merjenjem velikosti folikla z ultrazvokom in estrogenskega odziva.
Treatment should be tailored to the individual patient’s response as assessed by measuring follicle size by ultrasound and oestrogen response.
Zdravljenje mora biti prilagojeno odzivu posamezne bolnice, ki se oceni z merjenjem velikosti folikla z ultrazvokom in estrogenskim odzivom.
Treatment should be tailored to the individual patient’s response as assessed by measuring follicle size by ultrasound and/or oestrogen secretion.
Zdravljenje mora biti prilagojeno odzivu posamezne bolnice in se oceni z merjenjem velikosti folikla z ultrazvokom in/ali merjenjem izločana estrogena.
Treatment should be tailored to the individual patient’s response as assessed by measuring follicle size by ultrasound and/or oestrogen secretion.
Zdravljenje mora biti prilagojeno odzivu posamezne bolnice in se oceni z merjenjem velikosti folikla z ultrazvokom in/ali merjenjem izločanja estrogena.
Treatment should be tailored to the individual patient’s response as assessed by measuring follicle size by ultrasound and/or oestrogen secretion.
Zdravljenje mora biti prilagojeno odzivu posamezne bolnice in se oceni z merjenjem velikosti folikla z ultrazvokom in/ali merjenjem izločenega estrogena.
Treatment should be temporarily interrupted if the patient experiences certain side effects.
Če se pri bolniku pojavijo nekateri neželeni učinki, je treba zdravljenje začasno prekiniti.
Treatment should be under the suupervision of a physician experienced in the treatment of haemophilia.
Zdravljenje mora potekati pod naadzorom zdravnika z izkušnjami pri zdravljenju hemofilije.
Treatment should be under the suupervision of a physician experienced in the treatment of haemophilia.
Zdravljenje mora potekati pod nadzorom zdravnika z izkušnjami pri zdravljenju hemofilije.
Treatment should be withheld in patients with rhegmatogenous retinal detachment or stage 3 or 4 macular holes.
Pri bolnikih z regmatogenim odstopom mrežnice ali foramnom makule III. ali IV. stopnje je treba z zdravljenjem prenehati.
Treatment should consist of general supportive measures including monitoring of vital signs and ECG as well as observation of the patient’s clinical status.
Zdravljenje mora obsegati splošne podporne ukrepe, vključno z nadziranjem vitalnih znakov in EKG, ter opazovanje kliničnega stanja bolnika.
Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs that cannot be managed by concomitant medicinal products or dose adjustments.
Zdravljenje je treba nadaljevati tako dolgo, dokler je mogoče opaziti klinično korist oziroma dokler se ne pojavi nesprejemljiva toksičnost, ki je ni mogoče obvladovati s sočasno uporabljanimi zdravili ali s prilagajanjem odmerka.
Treatment should continue as long as clinical benefit is observed.
Z zdravljenjem je treba nadaljevati tako dolgo, dokler je pri bolniku mogoče opaziti klinične koristi.
Treatment should continue as long as the medicine has a benefit, but the dose can be reduced or treatment interrupted if the patient has side effects.
Zdravljenje je treba nadaljevati, dokler je zdravilo
Treatment should continue as long as the patient gets a benefit from it.
Zdravljenje se izvaja toliko časa, dokler je koristno za bolnika.
Treatment should continue for as long as the patient benefits from it or until the patient develops unacceptable side effects.
Zdravljenje je treba nadaljevati, dokler je za bolnika koristno oziroma do pojava nesprejemljivih neželenih učinkov.
Treatment should continue for as long as the patient continues to benefit.
Zdravljenje se izvaja tako dolgo, dokler še predstavlja korist za bolnika.
Treatment should continue for five weeks in patients who have had hip replacement surgery, and for two weeks in patients who have had knee replacement surgery.
Nadaljevati ga je treba pet tednov pri bolnikih po kirurški zamenjavi kolka in dva tedna pri bolnikih po kirurški zamenjavi kolena.
Treatment should continue for up to 1 year unless the disease gets worse or severe side effects develop.
Zdravljenje je treba nadaljevati do enega leta, razen če se bolezen poslabša ali se pojavijo resni neželeni učinki.
Treatment should continue in the case of stable disease, or partial or complete response, provided that the product is sufficiently well tolerated.
Zdravljenje naj se nadaljuje v primeru stabilnosti bolezni, delnega ali popolnega odgovora pod pogojem, da zdravljena žival zdravilo dobro prenaša.
Treatment should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs.
Zdravljenje je treba nadaljevati tako dolgo, dokler bolnik več nima kliničnih koristi od terapije ali do pojava nesprejemljive toksičnosti.
Treatment should last for at least for 3 weeks and continue until the patient’s symptoms resolve.
Zdravljenje mora trajati najmanj 3 tedne in dokler bolnikovi simptomi ne izginejo.
Treatment should normally not be initiated if ALT is >10 times the upper limit of normal.
Zdravljenja normalno ne smemo začeti, če so vrednosti ALT večje kot 10-kratna zgornja referenčna vrednost.
Treatment should not be initiated until it is reasonable to assume that a patient is stable following a period of intestinal adaptation.
Zdravljenje se ne sme začeti, dokler ni mogoče sklepati, da je bolnik stabilen po obdobju prilagajanja črevesa.
Treatment should not be initiated without providing a negative pregnancy test result to rule out unintended use in pregnancy (see section 4.3).
Zdravljenja ne smemo uvesti brez predložitve negativnega izvida testa nosečnosti (glejte poglavje 4.3).
Treatment should not be initiated without providing a negative pregnancy test result to rule out unintended use in pregnancy. .
Zdravljenja ne smemo uvesti brez predložitve negativnega izvida testa nosečnosti.
Treatment should not be restarted until the woman is completely mobilised.
Zdravljenje se ne sme začeti znova, dokler bolnica ni povsem mobilna.
Treatment should not be started or should be stopped in patients with abnormal liver enzyme levels in the blood (more
Pri bolnikih z nenormalno količino jetrnih encimov v krvi (več kot trikratne normalne vrednosti) se zdravljenje ne sme začeti ali se mora prekiniti.
Treatment should not be started or should be stopped in patients with abnormal liver enzyme levels in the blood (more
Pri bolnikih z nenormalno količino jetrnih encimov v krvi (za več kot trikratne normalne vrednosti) se zdravljenje ne sme začeti ali se mora prekiniti.
Treatment should not exceed two weeks.
Zdravljenje ne sme trajati dlje kot dva tedna.
Treatment should not usually be resumed earlier than 48 hours afterwards and only after renal function has been re-evaluated and found to be normal.
Zdravljenje se sme nadaljevati šele 48 ur po posegu in šele, ko se ponovno oceni delovanje ledvic in se ugotovi, da je normalno.
Treatment should not usually be resumed earlier than 48 hours afterwards, and only after renal function has been re-evaluated and found to be normal.
Zdravljenje se običajno lahko nadaljuje šele 48 ur po posegu in to šele, ko se ponovno oceni delovanje ledvic in se ugotovi, da je le-to normalno.
Treatment should only be given to patients with moderate anaemia (haemoglobin [Hb] concentration range between 10 to 13 g/dl [6.2 to 8.1 mmol/l], no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).
Zdravljenje se sme uporabiti samo pri bolnikih z zmerno anemijo (razpon koncentracije hemoglobina [Hb] od 10 do 13 g/dl [6,2 do 8,1 mmol/l] brez pomanjkanja železa), če postopki za ohranjanje krvi niso na voljo ali ne zadostujejo, kadar je za večji elektivni kirurški poseg potrebna velika količina krvi (4 ali več enot krvi za ženske ali 5 ali več enot za moške).
Treatment should only be initiated and monitored by a physician experienced in the treatment of CTEPH or PAH.
Zdravljenje mora uvesti in nadzirati zdravnik, ki ima izkušnje z zdravljenjem CTEPH ali PAH.
Treatment should only be initiated and monitored by a physician experienced in the treatment of pulmonary arterial hypertension.
Zdravljenje naj začne in vodi zdravnik z izkušnjami z zdravljenjem pljučne arterijske hipertenzije.
Treatment should only be initiated and monitored by a physician experienced in the treatment of systemic sclerosis.
Zdravljenje naj začne in vodi zdravnik z izkušnjami z zdravljenjem sistemske skleroze.